# US 2024/0199642 A1 · Method for obtaining rifapentine with a new crystalline form

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199642 A1
- Document ID: US20240199642A1
- Status: Published application
- Kind: A1
- Application number: 18/555,776
- Filed: 2021-04-21
- Published: 2024-06-20
- Earliest claimed: 2021-04-21
- Assignees: Interquim S.A. De C.V.
- Applicants: Interquim S.A. De C.V.
- Inventors: Aaeón RODRIGUEZ WELTON; Diego Armando PÉREZ ROJAS; Blanca Miriam SANTOYO TEPOLE
- Web page: https://patentgrep.com/patent/US20240199642A1

## CPC

- C07D 498/08: Bridged systems
- C07D 498/22: in which the condensed system contains four or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

A new crystalline form of rifapentine, the characterization thereof and a method for obtaining same is disclosed. The method for obtaining the new crystalline form includes the steps of adding a mixture of dimethylformamide, tert-butylamine and paraformaldehyde to rifamycin S in the presence of glacial acetic acid; adding paraformaldehyde and heating; subsequently adding 1-amino-4-cyclopentylpiperazine to dimethylformamide; adding ascorbic acid to water; and mixing, filtering and washing the product The yield of raw rifapentine is 87+5% with 99.00% purity.

## Claims

### Claim 1

A pure crystalline form of rifapentine having an X-ray powder diffraction pattern with the values shown in Table 1.

### Claim 2

The pure crystalline form of rifapentine having the X-ray powder diffractogram according to FIG. 1.

### Claim 3

A process for the preparation of the pure crystalline form of rifapentine comprising: mixing Dimethylformamide, tert-Butylamine and paraformaldehyde; adding Rifamycin S and glacial Acetic acid at 40° C.±5; adding paraformaldehyde and heating at 62-68° C. for 2 hours; adding a solution of 1-Amino-4-cyclopentyl piperazine in Dimethylformamide at a temperature of 68° C. for 16 hours; cooling the reaction mixture at 50° C.; adding a solution of ascorbic acid in water (400 mL) and mixing at 55-60° C.; adding ethyl acetate and water, cooling at 5-20° C.; filtering and washing the product with a mixture of Ethanol/water (1:1); squeezing and dry under vacuum at 60-65° C.; purify crude rifapentine and carry out re-pulping of the product.

### Claim 4 (depends on 3)

The process according to claim 3, characterized by the crude product is purified by dissolving the solid in a mixture of Ethanol and water (6:1) and heating at reflux for approximately 1 hour; cooling the mixture at 15-20° C. and filtering the pure Rifapentine; washing with a mixture of Ethanol/Water (1:1) and a second wash with 2 volumes of Water, squeeze and dry at 60-65° C. under vacuum.

### Claim 5 (depends on 3)

The process according to claim 3, characterized by the re-pulping stage in water is carried out by mixing the pure Rifapentine with 8 volumes of water, under stirring, filtering and washing with 1 volume of water; squeeze and dry under vacuum at 60° C. for 16 hours.

### Claim 6 (depends on 3)

The process according to claim 3, characterized by the yield of crude Rifapentine is 87±5% with a purity of 99.00%.

### Claim 7 (depends on 3)

The process according to claim 3, characterized by pure Rifapentine is obtained with a yield of 73±3% and a purity of 99.50%.

### Claim 8 (depends on 1)

A pharmaceutical composition having the pure crystalline form according to claim 1 as an active ingredient.
